NCT06021288 Standard Dose Continuous Renal Replacement Therapy (CRRT) Versus Low-Dose CRRT ( KETZEREI )
| NCT ID | NCT06021288 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Universität Münster |
| Condition | Critical Illness |
| Study Type | INTERVENTIONAL |
| Enrollment | 165 participants |
| Start Date | 2023-10-02 |
| Primary Completion | 2025-04-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 165 participants in total. It began in 2023-10-02 with a primary completion date of 2025-04-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Acute kidney injury (AKI) is a well-recognized complication in critically ill patients, which often leads to the necessity of mechanical kidney support (CRRT). In current therapeutic regimes, CRRT is used to strictly prevent azotaemia. Thus recent clinical observations, as well as data from animal testing suggest a link between controlled azotaemia and faster renal recovery in AKI patients. The aim of the study is to improve renal recovery.
Eligibility Criteria
Inclusion Criteria: * Adult patients (age ≥18 years) * Critically ill patients with AKI + in need of CRRT * Written informed consent Exclusion Criteria: * Chronic dialysis dependency * Chronic kidney disease with estimated glomerular filtration rate (eGFR) \<30 ml/min/1.73m² * severe liver cirrhosis (Child-pugh C) * severe acidosis (pH \< 7,20 at study enrolment) * severe hyperkalaemia (\> 6mmol/l) * Pregnancy or breastfeeding * persons held in an institution by legal or official order * Dependency on the investigator or center
Contact & Investigator
Alexander Zarbock, MD
STUDY CHAIR
WWU Münster
Frequently Asked Questions
Who can join the NCT06021288 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Critical Illness. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06021288 currently recruiting?
Yes, NCT06021288 is actively recruiting participants. Contact the research team at aki@anit.uni-muenster.de for enrollment information.
Where is the NCT06021288 trial being conducted?
This trial is being conducted at Münster, Germany, Tübingen, Germany.
Who is sponsoring the NCT06021288 clinical trial?
NCT06021288 is sponsored by Universität Münster. The principal investigator is Alexander Zarbock, MD at WWU Münster. The trial plans to enroll 165 participants.